Biocon soars as its arm launches Yesintek (ustekinumab-kfce) in United States
Biocon is currently trading at Rs. 328.00, up by 7.10 points or 2.21% from its previous closing of Rs. 320.90 on the BSE.
The scrip opened at Rs. 325.25 and has touched a high and low of Rs. 328.75 and Rs. 321.15 respectively. So far 42090 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 404.60 on 21-Jan-2025 and a 52 week low of Rs. 244.40 on 20-Mar-2024.
Last one week high and low of the scrip stood at Rs. 340.00 and Rs. 315.50 respectively. The current market cap of the company is Rs. 38581.28 crore.
The promoters holding in the company stood at 60.64%, while Institutions and Non-Institutions held 21.02% and 18.34% respectively.
Biocon’s subsidiary -- Biocon Biologics has launched Yesintek (ustekinumab-kfce) in the United States and is one of the first Stelara (ustekinumab) biosimilar market entrants in the country. Yesintek is approved for the treatment of Crohn’s disease, ulcerative colitis, plaque psoriasis and psoriatic arthritis, increasing patient access to more cost-effective treatment options for use in the treatment of common chronic autoimmune diseases.
Yesintek will be available in all the same formulations currently provided by Stelara. The available presentations are 45 mg/0.5 mL PFS, 90 mg/mL PFS, 45 mg/0.5 mL vial, and 130 mg/26 mL vial.
Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.
